Turn Therapeutics (TTRX) EBITDA (2024 - 2026)

Turn Therapeutics' EBITDA history runs 3 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 223.68% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$5.7 million (changed N/A YoY), while the FY2025 annual figure was -$5.9 million, down 226.0% from the prior year.
• EBITDA for Q1 2026 stood at -$1.2 million, up from -$2.2 million in the prior quarter.
• The five-year high for EBITDA was -$328957.0 in Q4 2024, with the low at -$2.2 million in Q4 2025.
• The 3-year median for EBITDA is -$959567.5 (2024), against an average of -$1.1 million.
• Peak annual rise in EBITDA reached 184.34% in 2025, while the deepest fall reached 566.83% in 2025.
• Turn Therapeutics' EBITDA stood at -$328957.0 in 2024, then plunged by 566.83% to -$2.2 million in 2025, then surged by 43.19% to -$1.2 million in 2026.
• Business Quant data shows TTRX's EBITDA at -$1.2 million in Q1 2026, -$2.2 million in Q4 2025, and -$1.9 million in Q3 2025.